LABP
Landos Biopharma, Inc. Common StockLABP
LABP
Delisted
LABP was delisted on the 23rd of May, 2024.
About: Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages. The company's pipeline includes NX-13, LABP-66, LAPB-73, LABP-69. The company's current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist.
Employees: 19
Financial journalist opinion
Neutral
PRNewsWire
1 year ago
AbbVie Completes Acquisition of Landos Biopharma
- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP).
Neutral
Business Wire
1 year ago
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (with a value of up to $11.14 per share, subject to the achievement of a clinical development milest.
Neutral
PRNewsWire
1 year ago
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie
MILWAUKEE , April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.
Neutral
Business Wire
1 year ago
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (with a value of up to $11.14 per share, subject to the achievement of a clinical development milest.
Neutral
PRNewsWire
1 year ago
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABP
NEW YORK , March 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Landos Biopharma, Inc. (NASDAQ: LABP), relating to its proposed sale to AbbVie, Inc. Under the terms of the agreement, LABP shareholders are expected to receive $20.42 in cash plus one non-tradable CVR worth up to $11.14 per share they own.
Positive
InvestorPlace
1 year ago
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
Landos Biopharma (NASDAQ: LABP ) stock is on the rise Monday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). AbbVie is acquiring Landos Biopharma for $20.42 per share in cash.
Neutral
PRNewsWire
1 year ago
Shareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVie
MILWAUKEE , March 25, 2024 /PRNewswire/ -- Ademi LLP is investigating Landos (NASDAQ: LABP) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.
Neutral
Business Wire
1 year ago
LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Landos Biopharma, Inc. (NASDAQ: LABP) to AbbVie Inc. is fair to Landos shareholders. Under the terms of the proposed transaction, AbbVie would acquire Landos for $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone. Halper Sadeh encourages Land.
Positive
Reuters
1 year ago
AbbVie to buy Landos to expand pipeline of immunity-related illnesses
AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.
Neutral
PRNewsWire
1 year ago
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
Charts implemented using Lightweight Charts™